OPTN Stock - OptiNose, Inc.
Unlock GoAI Insights for OPTN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $78.23M | $70.99M | $76.28M | $74.65M | $49.12M |
| Gross Profit | $71.00M | $62.35M | $67.01M | $65.50M | $41.60M |
| Gross Margin | 90.8% | 87.8% | 87.9% | 87.7% | 84.7% |
| Operating Income | $-16,319,000 | $-22,748,000 | $-55,896,000 | $-66,450,000 | $-87,219,000 |
| Net Income | $-21,541,000 | $-35,483,000 | $-74,833,000 | $-81,650,000 | $-98,330,000 |
| Net Margin | -27.5% | -50.0% | -98.1% | -109.4% | -200.2% |
| EPS | $-2.12 | $-0.32 | $-13.05 | $-1.44 | $-2.04 |
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| March 20th 2025 | Lake Street | Downgrade | Hold | - |
| January 3rd 2025 | H.C. Wainwright | Reiterated | Buy | $18← $5 |
| March 11th 2024 | H.C. Wainwright | Initiation | Buy | $5 |
| August 21st 2023 | Lake Street | Initiation | Buy | $3 |
| October 21st 2022 | Jefferies | Resumed | Buy | $5 |
Earnings History & Surprises
OPTNEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 10, 2025 | — | — | — | — |
Q3 2025 | Aug 14, 2025 | $-0.58 | — | — | — |
Q2 2025 | May 14, 2025 | $-0.74 | $-1.01 | -36.5% | ✗ MISS |
Q1 2025 | Mar 26, 2025 | $-0.70 | $-0.03 | +95.7% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.05 | $0.00 | +105.4% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-1.20 | $-1.05 | +12.5% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-1.50 | $-1.80 | -20.0% | ✗ MISS |
Q1 2024 | Mar 7, 2024 | $-1.50 | $-1.35 | +10.0% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-1.50 | $-1.20 | +20.0% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-1.65 | $0.30 | +118.2% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-2.40 | $-2.55 | -6.2% | ✗ MISS |
Q1 2023 | Mar 7, 2023 | $-2.40 | $-2.55 | -6.2% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-2.55 | $-2.70 | -5.9% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-3.30 | $-3.45 | -4.5% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-3.60 | $-4.65 | -29.2% | ✗ MISS |
Q1 2022 | Mar 8, 2022 | $-3.30 | $-3.45 | -4.5% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $-5.55 | $-4.80 | +13.5% | ✓ BEAT |
Q3 2021 | Aug 11, 2021 | $-6.45 | $-6.60 | -2.3% | ✗ MISS |
Q2 2021 | May 5, 2021 | $-7.80 | $-7.35 | +5.8% | ✓ BEAT |
Q1 2021 | Mar 3, 2021 | $-6.75 | $-6.90 | -2.2% | ✗ MISS |
Latest News
Frequently Asked Questions about OPTN
What is OPTN's current stock price?
What is the analyst price target for OPTN?
What sector is OptiNose, Inc. in?
What is OPTN's market cap?
Does OPTN pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to OPTN for comparison